Actavis, Perrigo Receive FDA Approval Of Guaifenesin/Pseudoephedrine

(RTTNews) - Actavis Plc. (ACT) and its partner Perrigo Co. Plc. (PRGO) Tuesday said Actavis has received U.S. Food and Drug Administration approval for its Abbreviated New Drug Application for guaifenesin/pseudoephedrine tablets.

Perrigo would begin shipments in time for the cough/cold season to its retail and wholesale customers in the U.S.

The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex D tablets.

Mucinex D (Guaifenesin/pseudoephedrine tablets), an expectorant indicated to relieve chest congestion and make coughs more productive, had sales of about $83 million through food, drug and mass merchandisers over the last 12 months.